Omacetaxine and azacitidine for untreated patients with myelodysplastic syndromes and excess blasts: a phase I/II clinical trial
HYPERLINCI, Edward P. Evans Foundation, Leukemia and Lymphoma Society Career Development Program, VA Merit, V-Foundation.
Authors
- Andrew Kent (ORCID: https://orcid.org/0000-0002-3680-5893)
- Sweta B. Patel (ORCID: https://orcid.org/0000-0001-7082-7204)
- Eric M. Pietras (ORCID: https://orcid.org/0000-0002-7339-8828)
- Daniel A. Pollyea (ORCID: https://orcid.org/0000-0001-6519-4860)
- Marc Schwartz
- Monica Ransom (ORCID: https://orcid.org/0000-0002-7527-7122)
- Craig T. Jordan (ORCID: https://orcid.org/0000-0003-0869-3465)
- Jonathan A. Gutman (ORCID: https://orcid.org/0000-0002-1470-0716)
- Brett M. Stevens (ORCID: https://orcid.org/0000-0002-9346-903X)
- Zenggang Pan (ORCID: https://orcid.org/0000-0003-4537-3356)
- Alexandra G. Ellis (ORCID: https://orcid.org/0000-0002-5128-0255)
- Christine M. McMahon (ORCID: https://orcid.org/0000-0001-9745-9595)
- Jeffrey Schowinsky (ORCID: https://orcid.org/0009-0009-8653-3820)
- Connor Sohalski
- Austin E. Gillen (ORCID: https://orcid.org/0000-0003-2928-6308)
- Mary Haag
- Clayton Smith
- Diana Abbott
- Maria Amaya
- Jessie Dell-Martin
Institutions
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- EClinicalMedicine
- Published
- 2025-10-11
- DOI
- https://doi.org/10.1016/j.eclinm.2025.103546
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00